0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > FOLR1

FOLR1

Brief Information

Name:Folate receptor alpha
Target Synonym:FRalpha,KB cells FBP,Adult folate-binding protein,Folate receptor 1,Folate receptor alpha,FR-alpha,FOLR1,Ovarian Tumor-Associated Antigen MOv18,Folate Receptor 1 (Adult),Folate Receptor, Adult,FOLR,FBP,Folate Binding Protein,FRα
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
FRα BsAb - 01 PCC Solid Tumor Ovarian cancer,Non-small cell lung cancer

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
FRα BsAb-ADC Bispecific antibody Oncology/Cancer Ovarian cancer Preclinical Global

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP091-Cell-based assay
 FOLR1 FACS

Expression analysis of human FOLR1 on HEK293/Human FOLR1 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human FOLR1 Stable Cell Line or negative control cell using PE-labeled anti-human FOLR1 antibody.

FO1-HP2H9-Cell-based assay
 FOLR1 FACS

5e5 of anti-FOLR1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human FOLR1, His Tag (Cat. No. FO1-HP2H9) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

FO1-C82E8-ELISA
 FOLR1 ELISA

Immobilized Anti-FOLR1 Antibody, Mouse IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus / Rhesus macaque FOLR1 Protein, His,Avitag (Cat. No. FO1-C82E8) with a linear range of 0.1-1 ng/mL (QC tested).

FO1-M5254-MALS-HPLC
FOLR1 MALS images

The purity of Mouse FOLR1 Protein, Fc Tag (Cat. No. FO1-M5254) is more than 90% and the molecular weight of this protein is around 100-125 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name

FOLR-1,FBP,FOLR

Background

Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Folinic Acid FTHF Approved Autism Spectrum Disorder; Down Syndrome; Rectal Neoplasms; Anemia; Diarrhea; Vitamin B 12 Deficiency; Colorectal Neoplasms Details
Mirvetuximab soravtansine M9346-Asulfo-SPDB-DM4; IMGN-853; M9346A-sSPDB-DM4 Approved Immunogen Inc Elahere United States Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial Immunogen Inc 2022-11-14 Ovarian Neoplasms; Solid tumours; Cystadenoma, Serous; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Neoplasms; Carcinosarcoma; Adenocarcinoma Details
Pafolacianine Sodium Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 Approved On Target Laboratories Inc Cytalux United States Ovarian Neoplasms On Target Laboratories Inc 2021-11-29 Ovarian Neoplasms; Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Neoplasms; Breast Neoplasms; Pituitary Neoplasms; Lung Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
4S-CAR-FRa 4S-CAR-FRa Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Carcinoma, Transitional Cell; Urinary Bladder Neoplasms Details
AZD5335 AZD5335; AZD-5335 Phase 2 Clinical Astrazeneca Plc Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung Details
CBP-1008 CBP-1008 Phase 2 Clinical Coherent Biopharma Suzhou Co Ltd Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell Details
Arfolitixorin ISO-901; 6R-MTHF Phase 3 Clinical Isofol Medical Ab Rectal Neoplasms; Colonic Neoplasms; Osteosarcoma; Colorectal Neoplasms Details
Farletuzumab MORAb-003 Phase 2 Clinical Morphotek Inc Ovarian Neoplasms; Solid tumours; Neoplasms; Carcinoma, Ovarian Epithelial; Adenocarcinoma of Lung; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
MOv19-BBz CAR-T cells Therapy Phase 1 Clinical University Of Pennsylvania Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
Rinatabart Sesutecan PRO-1184 Phase 2 Clinical ProfoundBio (Suzhou) Co Ltd Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Luveltamab tazevibulin STRO-002 Phase 2 Clinical Sutro Biopharma Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Endometrioid Details
MOv-18 IgE MOv-18 IgE; MOv18; MOv-18 Phase 1 Clinical King'S College London, Cancer Research UK Ovarian Neoplasms; Neoplasms Details
ITIL-306 ITIL-306 Phase 1 Clinical Instil Bio Inc Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung Details
IMGN-151 IMGN-151 Phase 1 Clinical Immunogen Inc Ovarian Neoplasms; Cystadenocarcinoma, Serous; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms Details
AMT-151 AMT-151 Phase 1 Clinical Solid tumours; Ovarian Neoplasms; Adenocarcinoma of Lung; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Mesothelioma; Adenocarcinoma, Clear Cell; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Carcinoma, Endometrioid; Adenocarcinoma Details
BAT-8006 BAT8006; BAT-8006 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
ELU-001 ELU-001 Phase 2 Clinical Elucida Oncology Inc Ovarian Neoplasms; Uterine Diseases; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Endometrioid; Neoplasm Metastasis; Adenocarcinoma Details
Noscapine-folate conjugate Phase 1 Clinical Emory University Hematologic Neoplasms; Inflammation Details
Farletuzumab ecteribulin MORAb-202 Phase 2 Clinical Eisai Co Ltd, Morphotek Inc, Bristol-Myers Squibb Company Solid tumours; Ovarian Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
UB-TT170 UB-TT170; UB-TT-170; UB_TT170; UB_TT-170 Phase 1 Clinical Umoja BioPharma Inc Osteosarcoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken